View Interim Results
Read More About Uniphar
Read Latest Investor News
Our vision is to improve patient access to pharmaco-medical products and treatments by developing connectivity between manufacturers and healthcare stakeholders.
Uniphar represents a strong combination of scale, growth and proﬁtability. In 2018, the Group generated revenue of €1.55 billion, gross proﬁt of €159.6 million and EBITDA of €46.3 million on a pro forma basis.
1. Unaudited pro forma financial information for the year ended 31 December 2018 for Uniphar plc, Sisk Healthcare and Durbin